Trial Profile

GBM AGILE: Global Adaptive Trial Master Protocol: An International, Seamless Phase II/III Response Adaptive Randomization Platform Trial Designed To Evaluate Multiple Regimens In Newly Diagnosed and Recurrent GBM

Status: Recruiting

Phase of Trial: Phase II/III

Latest Information Update: 29 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AZD 1390 (Primary) ; Dianhydrogalactitol (Primary) ; ERAS-801 (Primary) ; Paxalisib (Primary) ; Pegargiminase (Primary) ; Regorafenib (Primary) ; Troriluzole (Primary) ; VT-1021 (Primary) ; Lomustine; Temozolomide
Indications Glioblastoma; Gliosarcoma
Focus Registrational; Therapeutic Use
Acronyms GBM AGILE

15 May 2025 According to Kazia media release, company provided a regulatory update on paxalisib for the treatment of glioblastoma (GBM) following its Type C clinical meeting with the United States Food and Drug Administration (FDA).
13 May 2025 According to a Global Coalition for Adaptive Research media release, the company announced the activation of astraZeneca's AZD1390 in GBM AGILE. AZD1390 Arm Will Recruit Patients with Newly Diagnosed Glioblastoma Across Multiple International Trial Sites.
22 Nov 2024 According to the Global Coalition for Adaptive Research Media Release, new treatment AZD1390 arm has been added to the study.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com